Ontology highlight
ABSTRACT:
SUBMITTER: Flinn IW
PROVIDER: S-EPMC6284216 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
Flinn Ian W IW Hillmen Peter P Montillo Marco M Nagy Zsolt Z Illés Árpád Á Etienne Gabriel G Delgado Julio J Kuss Bryone J BJ Tam Constantine S CS Gasztonyi Zoltán Z Offner Fritz F Lunin Scott S Bosch Francesco F Davids Matthew S MS Lamanna Nicole N Jaeger Ulrich U Ghia Paolo P Cymbalista Florence F Portell Craig A CA Skarbnik Alan P AP Cashen Amanda F AF Weaver David T DT Kelly Virginia M VM Turnbull Barry B Stilgenbauer Stephan S
Blood 20181004 23
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In a phase 1 study, duvelisib showed clinically meaningful activity and acceptable safety in CLL/SLL patients. We report here the results of DUO, a global ...[more]